Balyasny Asset Management
SABS icon

Balyasny Asset Management’s SAB Biotherapeutics SABS Stock Holding History

Balyasny Asset Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.4M Buy
3,760,439
+3,285,000
+691% +$13.1M 0.02% 840
2025
Q4 		$1.78M Buy
+475,439
New +$1.56M ﹤0.01% 1925

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SSC
Spruce Street Capital New York $416M AUM

Balyasny Asset Management's SABS Position: Q1 2026 in Review

Balyasny Asset Management increased its SAB Biotherapeutics (SABS) stake by 691% in Q1 2026, buying an estimated $13.1M and bringing the position to 3,760,439 shares worth $14.4M. The position accounts for 0.02% of the portfolio, ranked #840.

Balyasny Asset Management first reported a position in SABS in Q4 2025 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Balyasny Asset Management held 3,760,439 shares of SAB Biotherapeutics worth $14.4M as of Q1 2026.
  • Balyasny Asset Management bought 3,285,000 SAB Biotherapeutics shares in Q1 2026, an estimated $13.1M.
  • SAB Biotherapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #840 holding.
  • Balyasny Asset Management first reported a position in SAB Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.